Table 1. Trends in crude incidence rates and age-standardized incidence rates of myeloproliferative neoplasm in Korea by incidence from 2003 to 2011.
MPN type | Sex | Year | APC | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | ||||
MPN total | Total | Cases | 260 | 288 | 406 | 402 | 476 | 538 | 628 | 643 | 701 | |
CR | 0.54 | 0.59 | 0.83 | 0.82 | 0.97 | 1.09 | 1.26 | 1.29 | 1.40 | |||
ASR | 0.50 | 0.53 | 0.73 | 0.71 | 0.81 | 0.89 | 0.99 | 0.99 | 1.05 | 9.9* | ||
Men | Cases | 135 | 152 | 212 | 214 | 261 | 282 | 310 | 337 | 380 | ||
CR | 0.56 | 0.63 | 0.87 | 0.87 | 1.06 | 1.14 | 1.25 | 1.35 | 1.52 | |||
ASR | 0.55 | 0.62 | 0.83 | 0.82 | 0.96 | 1.01 | 1.07 | 1.13 | 1.23 | 10.0* | ||
Women | Cases | 125 | 136 | 194 | 188 | 215 | 256 | 318 | 306 | 321 | ||
CR | 0.52 | 0.56 | 0.80 | 0.77 | 0.88 | 1.04 | 1.28 | 1.23 | 1.28 | |||
ASR | 0.45 | 0.47 | 0.66 | 0.63 | 0.67 | 0.80 | 0.94 | 0.87 | 0.91 | 9.8* | ||
PV | Total | Cases | 118 | 125 | 165 | 149 | 196 | 178 | 221 | 228 | 202 | |
CR | 0.24 | 0.26 | 0.34 | 0.30 | 0.40 | 0.36 | 0.45 | 0.46 | 0.40 | |||
ASR | 0.23 | 0.23 | 0.30 | 0.26 | 0.34 | 0.30 | 0.35 | 0.35 | 0.31 | 4.9* | ||
Men | Cases | 70 | 77 | 100 | 101 | 131 | 114 | 131 | 138 | 115 | ||
CR | 0.29 | 0.32 | 0.41 | 0.41 | 0.53 | 0.46 | 0.53 | 0.55 | 0.46 | |||
ASR | 0.28 | 0.31 | 0.39 | 0.38 | 0.49 | 0.41 | 0.45 | 0.46 | 0.37 | 4.6* | ||
Women | Cases | 48 | 48 | 65 | 48 | 65 | 64 | 90 | 90 | 87 | ||
CR | 0.20 | 0.20 | 0.27 | 0.20 | 0.27 | 0.26 | 0.36 | 0.36 | 0.35 | |||
ASR | 0.17 | 0.16 | 0.22 | 0.15 | 0.20 | 0.19 | 0.25 | 0.23 | 0.23 | 4.7* | ||
MF | Total | Cases | 37 | 38 | 53 | 51 | 67 | 77 | 88 | 73 | 76 | |
CR | 0.08 | 0.08 | 0.11 | 0.10 | 0.14 | 0.16 | 0.18 | 0.15 | 0.15 | |||
ASR | 0.07 | 0.07 | 0.09 | 0.09 | 0.11 | 0.12 | 0.13 | 0.11 | 0.11 | 7.2* | ||
Men | Cases | 20 | 23 | 28 | 29 | 34 | 45 | 49 | 47 | 47 | ||
CR | 0.08 | 0.09 | 0.11 | 0.12 | 0.14 | 0.18 | 0.20 | 0.19 | 0.19 | |||
ASR | 0.08 | 0.10 | 0.11 | 0.11 | 0.12 | 0.16 | 0.16 | 0.16 | 0.15 | 8.5* | ||
Women | Cases | 17 | 15 | 25 | 22 | 33 | 32 | 39 | 26 | 29 | ||
CR | 0.07 | 0.06 | 0.10 | 0.09 | 0.13 | 0.13 | 0.16 | 0.10 | 0.12 | |||
ASR | 0.06 | 0.05 | 0.08 | 0.07 | 0.10 | 0.10 | 0.10 | 0.08 | 0.07 | 4.7 | ||
ET | Total | Cases | 105 | 125 | 188 | 202 | 213 | 283 | 319 | 342 | 423 | |
CR | 0.22 | 0.26 | 0.39 | 0.41 | 0.43 | 0.57 | 0.64 | 0.69 | 0.84 | |||
ASR | 0.20 | 0.23 | 0.34 | 0.36 | 0.36 | 0.47 | 0.51 | 0.53 | 0.64 | 14.6* | ||
Men | Cases | 45 | 52 | 84 | 84 | 96 | 123 | 130 | 152 | 218 | ||
CR | 0.19 | 0.21 | 0.34 | 0.34 | 0.39 | 0.50 | 0.52 | 0.61 | 0.87 | |||
ASR | 0.19 | 0.22 | 0.33 | 0.33 | 0.35 | 0.44 | 0.45 | 0.51 | 0.71 | 15.8* | ||
Women | Cases | 60 | 73 | 104 | 118 | 117 | 160 | 189 | 190 | 205 | ||
CR | 0.25 | 0.30 | 0.43 | 0.48 | 0.48 | 0.65 | 0.76 | 0.76 | 0.82 | |||
ASR | 0.21 | 0.25 | 0.36 | 0.40 | 0.36 | 0.51 | 0.58 | 0.55 | 0.60 | 13.6* |
CR, crude rate; ASR, age-standardized rate; APC, annual percentage change; MPN, myeloproliferative neoplasm; PV, polycythemia vera; MF, primary myelofibrosis; ET, essential thrombocythemia.
*The annual percent change is statistically significantly different from zero (P < 0.05).